Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Pizotyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.69 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 7/20 | 0.69 |
| ▸ | HTR2C | P28335 | 7/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.69 |
| ▸ | DRD3 | P35462 | 6/20 | 0.69 |
| ▸ | HTR2B | P41595 | 6/20 | 0.69 |
| ▸ | HRH1 | P35367 | 5/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.69 |
| ▸ | DRD1 | P21728 | 5/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pizotyline SCHEMBL44122 | 0.83 | DRD1 (1.00) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| Pizotyline SCHEMBL8771138 | 0.83 | DRD1 (1.00) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| Pizotyline SCHEMBL29366884 | 0.83 | DRD1 (1.00) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| Pizotyline SCHEMBL1000901 | 0.83 | MAPK1 (1.00) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| Pizotyline SCHEMBL1000902 | 0.83 | MAPK1 (1.00) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| Pizotyline SCHEMBL11436430 | 0.82 | DRD1 (0.97) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| SCHEMBL11601745 | 0.77 | MAPK1 (0.69) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| SCHEMBL11602084 | 0.75 | DRD3 (0.65) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| SCHEMBL3694376 | 0.74 | HRH1 (0.65) | CYP2D6CYP2C19MAPK1MEN1MAPT | |
| SCHEMBL3789710 | 0.74 | MAPK1 (0.60) | CYP2D6CYP2C19MAPK1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | UNM RAINFOREST INNOVATIONS | 2020-03-10 | — | — | US | claimed |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | UNM RAINFOREST INNOVATIONS | 2019-09-05 | — | — | US | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| EP-4424363-B1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599602-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-04-14 | — | — | US | disclosed |
| US-12576079-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-03-17 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-12281301-B2 | Sequencing-based proteomics | THE BROAD INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-1224366-A | Pharmaceutical administration form | MUELLER D (DE) | 1999-07-28 | — | — | CN | disclosed |
| EP-0907388-A1 | PHARMACEUTICAL ADMINISTRATION FORM | Müller, Dieter (DE) | 1999-04-14 | — | — | EP | disclosed |
| WO-1998000198-A1 | PHARMACEUTICAL ADMINISTRATION FORM | MUELLER DIETER (DE) | 1998-01-08 | — | — | WO | disclosed |
| EP-0805680-A2 | COMBINATIONAL DRUGS FOR TREATING MIGRAINE AND OTHER ILLNESSES, COMPRISING SESQUITERPENE LACTONES AND B-COMPLEX VITAMINS | Ashbury Research Corporation (CA) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022774-A2 | COMBINATIONAL DRUGS FOR TREATING MIGRAINE AND OTHER ILLNESSES, COMPRISING SESQUITERPENE LACTONES AND B-COMPLEX VITAMINS | ASHBURY RESEARCH CORPORATION (CA) | 1996-08-01 | — | — | WO | disclosed |
| EP-0098041-B1 | SESQUITERPENE LACTONES, EXTRACTS CONTAINING THEM, THEIR PREPARATION AND PHARMACEUTICAL USE | R.P. SCHERER CORPORATION (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4758433-A | Oil extract of Tanacetum parthenium for treating migraine | R. P. SCHERER CORP. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0098041-A2 | Sesquiterpene lactones, extracts containing them, their preparation and pharmaceutical use | R.P. SCHERER CORPORATION (US) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | DRD2 4216/4885HTR1B 2411/4885CYP2D6 3894/4885 |
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | DRD2 4578/4885HTR1B 2870/4885CYP2D6 1785/4885 |
| US-12599602-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | DRD2 3131/4885HTR1B 2412/4885CYP2D6 1436/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | DRD2 4342/4885HTR1B 2189/4885CYP2D6 201/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | DRD2 3656/4885HTR1B 1570/4885CYP2D6 386/4885 |
| US-12576079-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | DRD2 4715/4885HTR1B 3510/4885CYP2D6 3141/4885 |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | BECN1, RABGGTB, TFEB | DRD2 165/4885HTR1B 2797/4885CYP2D6 1384/4885 |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | BECN1, TFEB, ATG7 | DRD2 594/4885HTR1B 1403/4885CYP2D6 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.